COLA: Asthma Guidelines

Session recorded on:   September 7, 2018

Speaker:  Michael Foggs, MD 

Price: $25 members,  $35 non-members

Viewers can earn credit by completing the posttest questions.


This CME activity is designed to improve competence in diagnosing asthma, ascertaining, asthma severity, determining the correct level of asthma control, and also to decrease frequency of asthma exacerbations that can lead to premature loss of lung function, airways remodeling, and asthma mortality.

Target Audience

Practicing Allergists / Immunologists

Learning Objectives

After viewing the video recording, learners should be able to:

Describe the asthma paradigm of current impairment & future risk.
Define asthma severity & asthma control & distinguish between the two.
Discuss mechanisms by which airway remodeling can occur.
Articulate potential damage to the airways caused by an asthma exacerbation.

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner
Speaker, Honorarium: Thermofisher, Boehringer Ingelheim

Michael B. Foggs, MD, Speaker
Consultant/Speaker, Fees/Honorarium: AstraZeneca, Boehringer Ingelheim, Genentech, Noavartis
Consultant, Fees: Boston Scientific, Mylan, Teva

The following have no financial relationships to disclose:

Paul Dowling, MD, Planner

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance


Please login or create an account to take this course.